Insurer Sigma Reverses Denials After Viral Campaign, Approves Liver Transplant Candidate and Triggers Oversight Scrutiny

Insurance Denials Block liver transplant For Patient With Cholangiocarcinoma, Approval Follows Social Outcry

USA: A Colorado man fighting cholangiocarcinoma endured repeated insurance denials for therapies intended to make him eligible for a lifesaving liver transplant. Diagnosed as one of roughly 8,000 U.S. cases each year, the patient’s scan revealed massive liver tumors—one nearly 11 centimeters, roughly the size of a grapefruit—and an initial chemotherapy regimen failed to control the disease. His care team shifted to a targeted therapy strategy aimed at shrinking the tumors to prepare him for a transplant.

The patient, identified as Katon, and his wife, Tori, spent hours on the phone filing appeals after an insurer repeatedly ruled treatments not medically necessary. Documents in the public record show at least one denial was signed off by an OB-GYN on the insurer’s review team. National data from KFF underscore the scale of the problem: in 2023 federal health insurers denied about one in five claims, with fewer than 1% of patients pursuing appeals.

Frustrated and pushed to the margins of the appeal process, Tori turned to LinkedIn to seek help and accountability. Her post drew hundreds of reposts and a flood of messages to the insurer. Days later the patient was notified that his treatment had been approved. When the insurer later denied coverage for the planned liver transplant itself, another wave of social media response preceded a second reversal and approval. The family says they cannot prove the public pressure caused the changes, and the insurer maintains social media does not influence coverage decisions.

Advocates and the family say the case highlights how administrative decisions can obstruct access to transplantation and cancer care, and they call for insurers to treat applicants as people requiring urgent, evidence-driven care. The episode drew regional attention in Denver and has reignited debate about appeal processes, review practices, and timely access to transplant-related therapies.

Video originally published on 2026-02-19 12:50:28